The state of Massachusetts currently has 6 active clinical trials seeking participants for NASH - Nonalcoholic Steatohepatitis research studies. These trials are conducted in various cities, including Boston, Worcester, Springfield and Burlington.
A Study Evaluating Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Recruiting
The aim of this study is to assess the safety and tolerability of EFX compared to placebo in subjects with non-invasively diagnosed NASH/MASH and NAFLD/MASLD.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
06/04/2024
Locations: Akero Clinical Study Site, South Dartmouth, Massachusetts
Conditions: NASH/MASH, NAFLD/MASLD
A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
Recruiting
This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in subjects with non-cirrhotic NASH/MASH and fibrosis stage 2 or 3.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
06/04/2024
Locations: Akero Clinical Study Site, South Dartmouth, Massachusetts
Conditions: NASH With Fibrosis, MASH With Fibrosis
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )
Recruiting
This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis histological stage F2 or F3
Gender:
All
Ages:
18 years and above
Trial Updated:
01/24/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts +3 locations
Conditions: NASH - Nonalcoholic Steatohepatitis
A Physiologic Analysis of Endoscopic Sleeve Gastroplasty (ESG)
Recruiting
Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease worldwide. Affecting approximately one-third of the United States (U.S.) population, the prevalence of NAFLD increases to 90% in patients with obesity. In 25% of patients, NAFLD progresses to a more severe form-non-alcoholic steatohepatitis (NASH)-which further increases the risks of cirrhosis and hepatocellular carcinoma. In 2017, the lifetime costs of caring for NASH patients in the U.S. were estimated at $222.6... Read More
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
11/14/2023
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Endoscopic Sleeve Gastroplasty, Liver Function, Obesity, Non-alcoholic Steatohepatitis (NASH), Non-alcoholic Fatty Liver Disease (NAFLD), Endoscopic Ultrasound, Liver Fibroses
The Impact of Ibutamoren on Nonalcoholic Fatty Liver Disease
Recruiting
Nonalcoholic fatty liver disease (NAFLD), fatty infiltration of the liver in the absence of alcohol use, is an increasingly recognized complication of obesity, with prevalence estimates of about 30% of individuals in the United States. A subset of these will develop progressive disease in the form of nonalcoholic steatohepatitis (NASH), which can progress to cirrhosis and liver failure. The investigators hypothesize that LUM-201 (Ibutamoren mesylate) will decrease intrahepatic lipid accumulation... Read More
Gender:
All
Ages:
Between 21 years and 60 years
Trial Updated:
10/24/2023
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: NAFLD, Nonalcoholic Fatty Liver, NASH - Nonalcoholic Steatohepatitis
Estrogen Administration for the Treatment of NASH in Postmenopausal Women
Recruiting
Non-alcoholic fatty liver disease (NAFLD) is a growing epidemic in the United States. Despite this, the treatment options remain limited. Preclinical and preliminary clinical data suggest that estrogen deficiency plays an important role in the pathology of steatosis, inflammation and fibrosis in non-alcoholic steatohepatitis (NASH), the progressive form of NAFLD. Post-menopausal women are a growing population with particularly high risk of NASH due to their lack of estrogen. This study will exam... Read More
Gender:
Female
Ages:
Between 45 years and 70 years
Trial Updated:
04/07/2023
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: NASH - Nonalcoholic Steatohepatitis